Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06017050 · ClinicalTrials.gov registry record · NA
BullyDown, a Text Messaging-based Bullying Prevention Program for Middle School-aged Youth
A NA study of Bullying, sponsored by Center for Innovative Public Health Research.
- Completed
- Registry status
- NA
- Development phase
- 138
- Enrollment target
- 2
- Study locations
NCT06017050: Completed NA study of Bullying, sponsored by Center for Innovative Public Health Research.
NCT06017050 is a NA study of Bullying that has completed, run by Center for Innovative Public Health Research. The registered enrollment target is 138 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06017050, a NA study of Bullying, has completed, sponsored by Center for Innovative Public Health Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 138 participants
- Enrollment target
- 2
- Study locations
Study Summary
Given the limited impact of existing school-based interventions and the time associated with implementing them during school time, more efficient and effective intervention methods are needed. Programs that can be delivered to middle school youth irrespective of whether they are attending school physically or virtually may be especially relevant as school boundaries become more fluid. BullyDown addresses this critical need by providing a scalable program that could be quickly and cost-effectively disseminated nationally.
Primary Outcome
If at least 75% of eligible participants assent to participate, this will be supportive of a hypothesis of feasibility. Note that a youth could assent and not be randomized if they did not complete the baseline survey.
Conditions Studied
Interventions
- BEHAVIORAL BullyDown
- BEHAVIORAL Attention-matched control
Study Locations (2)
California
- Center for Innovative Public Health Research - San Clemente
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2023-08-15 |
| Est. Completion | 2024-06-03 |
| Phase | NA |
What the finished NCT06017050 record still lists
NCT06017050 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Bullying appearing as the primary indexed condition, and to 2 interventions - of which BullyDown is the first listed.
NCT06017050 reports a single indexed study location in California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06017050 about?
NCT06017050 is a clinical study titled "BullyDown, a Text Messaging-based Bullying Prevention Program for Middle School-aged Youth". Given the limited impact of existing school-based interventions and the time associated with implementing them during school time, more efficient and effective intervention methods are needed. Programs that can be delivered to middle school youth irrespective of whether they are attending school phy...
What is the current status of trial NCT06017050?
This trial is currently completed. It is a NA study. The enrollment target is 138 participants. The study started on 2023-08-15. Estimated completion is 2024-06-03.
What conditions does trial NCT06017050 study?
This clinical trial studies the following conditions: Bullying.
What interventions are being tested in trial NCT06017050?
The interventions under investigation include: BullyDown (BEHAVIORAL), Attention-matched control (BEHAVIORAL).
Who is sponsoring clinical trial NCT06017050?
This trial is sponsored by Center for Innovative Public Health Research, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06017050 being conducted?
This trial has 2 study locations across California, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bullying
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06017050's enrollment target sits among peer trials
138 720th of 2000 higher than 1,279 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI